SFI Enhances Therapeutic Efficiency of Gefitinib: An Insight into Reversal of Resistance to Targeted Therapy in Non-small Cell Lung Cancer Cells

Conclusions: Taken together, MAPK/SREBP1 pathway could be regarded as the potential treatment target for overcoming resistance to EGFR-TKIs in NSCLC and adjuvant therapy of SFI could be a potential therapeutic strategy for gefitinib resistant treatment.

http://www.jcancer.org/v11p0334.htm

Source: Journal of Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Zhenzhen Pan, Kai Wang, Qiufang Chen, Xiulan Zheng, Zhengyu Song, Xuansheng Ding Tags: Research Paper Source Type: research

More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Study